The Rise of Biosimilars: Regulatory Pathways and Market Outlook
Biosimilars are changing the way healthcare systems manage the high cost of advanced medicines.
September 19, 2025
by Nurah Ekhlaque
Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
April 28, 2025
by Kevin
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
Telix announces that the ANVISA has approved Illuccix® the Company's lead prostate cancer imaging agent.
March 18, 2025
by PR Newswire
Illuccix® Approved in the United Kingdom
Telix today Announces that UK Medicines and MHRA has Approved the MAA for its prostate cancer medicine.
February 13, 2025
by PR Newswire
Drug Marketing in China and Worldwide (August)(2023)
The official website shows that the drugs developed by major companies have been declared for marketing.
September 1, 2023
by PharmaSources
A Review of Oncology Biosimilars Products and Companies
Biologics and biosimilars are large and generally complex therapeutics produced from living organisms.
May 12, 2022
by David Orchard-Webb
Pharmaceutical News of the Week (June.22-27) | PharmaSources.com
With the last week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 22-28, including 22 pieces.
July 1, 2020
by PharmaSources/Caicai
Pharmaceutical News of the Week (June.15th-19th)| PharmaSources.com
With the third week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 15-19.
June 23, 2020
by PharmaSources/Caicai
Pharmaceutical News of the Week June 8th-12th | PharmaSources.com
With the second week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 8-12.
June 22, 2020
by PharmaSources/Caicai
Pharmaceutical News of the Week (June 5th) | PharmaSources.com
With the first week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved approval, R&D, policies, transactions, and marketing that happened during June 1-5, including 21 pieces.
June 11, 2020
by PharmaSources/Caicai
Glenmark announces approval for Ryaltris in Australia
Glenmark Pharmaceuticals has announced that Seqirus Pty. Ltd. (Seqirus) has received marketing approval for Ryaltris® from the Therapeutic Goods Administration (TGA), Australia. This paves the way for the launch of Ryaltris® in Australia through the partn
December 22, 2019
by biospectrumasia
New cancer drugs approvals underpinned by flawed evidence
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
September 20, 2019
by europeanpharmaceuticalreview